Clinical trials: Prostatic Disease
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer
Cabozantinib in Men With Castration-Resistant Prostate Cancer
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01703065
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Bladder Neck Obstruction, Benign Prostate Hyperplasia
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia
The purpose of this study is to assess the safety and efficacy of MediTate Temporary Implantable Nitinol Device (TIND) used to alleviate symptoms of Bladder Outlet Obstruction (BOO) secondary to Benign Prostate Hyperplasia…
- Trial name
- NCT01436877
- Testing
- Insertion of Temporary Implantable Nitinol Device (TIND)
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Medi-Tate Ltd.
Prostate Cancer
Predicting Prostate Biopsy Results With Biomarkers and mpMRI.
Current standard prostate biopsy techniques, used to definitively diagnose prostate cancer (PC), utilises an ultrasound guided biopsy approach, that offers unsatisfactory specificity and sensitivity for clinical significant PC.
- Trial name
- ProBioM (NCT03730324)
- Testing
- mpMRI, Urine and plasma biomarkes.
- Where
- Denmark
- Volunteers
- 261 people
- Sponsor
- Torben Brøchner Pedersen
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter
A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.
- Trial name
- EVEREST-I (NCT03423979)
- Testing
- Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel
- Where
- 5 sites in Dominican Republic, Panama
- Volunteers
- 80 people
- Sponsor
- Urotronic Inc.
Prostate Cancer
Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)
The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal.
- Trial name
- NCT04486846
- Testing
- eVisit
- Where
- 4 sites in United States
- Sponsor
- Duke University
Prostate Cancer
Evaluation of the Practice of the TEP Choline at Patients With Prostate Cancer
The prostate cancer is a heterogeneous disease the care of which varies according to the status: localized, locally advanced, or in recurrence after local or metastatic treatment.
- Trial name
- TEPCholine (NCT03201380)
- Testing
- TEP scanner with choline
- Volunteers
- 300 people
- Sponsor
- Institut Paoli-Calmettes
Benign Prostatic Hyperplasia
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath
To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT05400980
- Testing
- Urocross implant
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Prodeon Medical, Inc
Malnutrition, Prostate Cancer
Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer
RATIONALE: An individualized, computer-designed health program may promote changes in diet and physical activity and may improve quality of life in patients who have early-stage prostate cancer.
- Trial name
- NCT00044980
- Testing
- nutritional support, quality-of-life assessment
- Where
- United States
- Sponsor
- Duke University
Prostate Cancer
Irish Programme for Stratified Prostate Cancer Therapy
The purpose of the trial is to investigate new clinical tests that could predict what treatments work best for certain patients with advanced prostate cancer by identifying markers and indicators present in blood and tissue which…
- Trial name
- iPROSPECT (NCT03162003)
- Where
- 9 sites in Ireland
- Volunteers
- 55 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer, Castration Resistant
Multi-academic Center Study of Xofigo Patients
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival…
- Trial name
- NCT03419442
- Testing
- Xofigo, Taxotere, Jevtana
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bayer
Prostate Cancer
Long-term Outcomes of Prostate Cancer Screening
This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and…
- Trial name
- STHLM3MRI_3 (NCT07155759)
- Testing
- PSA/Stockholm3/MRI, PSA
- Where
- Sweden
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Non-Small Cell Lung Cancer, Prostate Cancer
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate…
- Conditions
- Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
- Trial name
- NCT00743379
- Testing
- TH-302
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Threshold Pharmaceuticals
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00936390
- Testing
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy
- Where
- 518 sites in United States, Canada
- Volunteers
- 1,538 people
- Sponsor
- Radiation Therapy Oncology Group
Benign Prostatic Hyperplasia (BPH)
The FLOW Registry.
The purpose of this study is to create a database and prospective registry for data collection on patients with benign prostatic hyperplasia undergoing Aquablation of the prostate.
- Trial name
- NCT07430423
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- University of Chicago
Prostatic Neoplasms
Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II
A new method for localization of the prostate during external beam radiotherapy. The method is based on insertion of a new thermo-expandable Ni-Ti stent.
- Trial name
- NCT00250224
- Testing
- Radiotherapy stent
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Aalborg University Hospital
Prostate Cancer
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
This Phase II single dose study was designed to characterize the safety, tolerability, and efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with hormone refractory prostate cancer.
- Trial name
- NCT00667862
- Testing
- Panobinostat
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Lower Urinary Tract Symptoms
Effect of Enhanced External Counterpulsation on Lower Urinary Tract Symptoms
The purpose of this study is to access the effects of Enhanced External Counterpulsation treatment on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
- Trial name
- EECPLUTS (NCT01815697)
- Testing
- Enhanced External Counterpulsation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Benign Prostatic Hyperplasia (BPH)
PERmixon® in LUTS Evaluation Study (PERLES)
The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment.
- Trial name
- PERLES (NCT02121613)
- Testing
- Permixon® 160 mg, Tamsulosine LP
- Where
- 58 sites in Czechia, France and 3 more
- Volunteers
- 833 people
- Sponsor
- Pierre Fabre Medicament
Prostate Cancer
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Men with elevated prostate specific antigen bloodtest and prior negative prostate biopsy have a 30-60% of harboring occult prostate cancer.
- Trial name
- NCT02138760
- Testing
- MRI UroNav fusion biopsy
- Where
- 2 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Prostate Cancer
A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer
Prostate cancer is the most common male cancer in the UK with 35,000 cases diagnosed annually. 35% of these are locally advanced disease.
- Trial name
- PIVOTAL (NCT01685190)
- Testing
- Prostate alone IMRT, Prostate and pelvis IMRT
- Where
- 7 sites in United Kingdom
- Volunteers
- 124 people
- Sponsor
- Institute of Cancer Research, United Kingdom
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.